Among stocks seeing big moves in after-hours trading Thursday, AbCellera Biologics (ABCL) gained after saying it won emergency use authorization from the Food and Drug Administration for a treatment of people who’ve been exposed to COVID. The company said its bamlanivimab drug can now be used in combination with another drug called etesevimab “to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination.”
The move “provides....More>>>